Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)

NCT07764978 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07764978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
June 26, 2026
Completion date
May 12, 2034
Enrollment
750 (estimated)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma